Reck M, et al. - The overall survival findings of the phase III LUME-Lung 1 study led to the approval of nintedanib in combination with docetaxel in the European Union and other countries for the treatment of advanced non-small-cell lung cancer (NSCLC) of adenocarcinoma histology after first-line chemotherapy, so researchers assessed change in target lesion size over time in patients from this study. They found a significantly decreased tumor burden and decelerated tumor size over time in patients treated with nintedanib/docetaxel vs placebo/docetaxel. This finding was true for the overall adenocarcinoma population, including patients with the poorest prognosis because of aggressive tumor dynamics.